empagliflozin

Known as: (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol, 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene 
 
National Institutes of Health

Related topics

Related topics

13 relations

Narrower (3)

BI 10773GlyxambiJardiance

Broader (3)

Benzhydryl CompoundsGlucosidesHypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors [MoA]empagliflozin / Linagliptinempagliflozin / Metforminempagliflozin 10 MG / Linagliptin 5 MG Oral Tablet [Glyxambi]
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Early Glycaemic Control in Metformin Users Receiving Their First Add-On Therapy: A Population-Based Study of 4,734 People with… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
BACKGROUND Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial… (More)
  • table 1
  • figure 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
AIMS We previously reported that in the EMPA-REG OUTCOME(®) trial, empagliflozin added to standard of care reduced the risk of 3… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
OBJECTIVE To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
BACKGROUND Diabetes is a leading cause of chronic kidney disease (CKD) worldwide. Optimum glycaemic control in patients with type… (More)
  • figure 1
  • table 1
  • table 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
BACKGROUND Metformin is the recommended first-line pharmacotherapy for patients with type 2 diabetes. There is no consensus on… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
AIMS This study investigated the efficacy and tolerability of empagliflozin as add-on to pioglitazone ± metformin in patients… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
OBJECTIVE To investigate the efficacy and tolerability of empagliflozin as add-on to metformin and sulfonylurea in patients with… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin
OBJECTIVE To investigate the long-term safety and efficacy of empagliflozin, a sodium glucose cotransporter 2 inhibitor… (More)
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
AIMS Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in clinical development for the treatment of… (More)
Is this relevant?